Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ubium Group is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution is being conducted by 1 distinct examiner, which points to an area of research or development. This concentration allows for a focus on the technical merits of the pending application during the prosecution phase.
The busiest examiner, CHEN, CATHERYNE, is responsible for 1 busiest examiner pending action. Given that the portfolio includes 1 distinct examiner, this individual is responsible for all current pending actions. The prosecution is situated within 1 distinct art unit, ensuring that the examination remains within an administrative group. This creates a point of contact for all current prosecution matters handled by the office.
Managing 1 pending office action in the Biotechnology & Pharmaceuticals sector suggests an intellectual property strategy. The use of 1 distinct art unit limits the complexity of the prosecution. This environment is for maintaining arguments and responses during the examination of the company's current patent efforts. Practitioners can focus their resources on the requirements of the 1 examiner involved in the case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, CATHERYNE | 1 | 37.4% | +18.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 15790970 | Process For Producing A Fluid Soluble Cannabis Base Product | CHEN, CATHERYNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 15790970 | Process For Producing A Fluid Soluble Cannabis Base Product | CHEN, CATHERYNE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 15790970 | Process For Producing A Fluid Soluble Cannabis Base Product | CHEN, CATHERYNE | 1655 | §103§112 | Final Rejection | — | Pending | Oct 23, 2017 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial